MSF raises concerns over FTA impact on medicines in India, Pg14

Key Highlights:

• Médecins Sans Frontières (MSF) has voiced concerns to the European Union regarding the potential impact of the EU-India Free Trade Agreement on access to medicines.
• MSF fears the agreement may strengthen the monopoly rights of multinational pharmaceutical manufacturers, negatively affecting patients in India and developing countries.
• The organization is specifically worried about provisions like data exclusivity, patent term extensions, and border measures that could hinder generic competition.

Detailed Insights:

• The proposed provisions in the EU-India FTA could limit or block generic competition, which has been crucial in lowering medicine prices.
• Data exclusivity can obstruct the issuance of compulsory licenses, which allow generic manufacturers to produce medicines even when they are patented.
• Patent term extensions prolong the period of market exclusivity for pharmaceutical companies, delaying the entry of more affordable generic versions.
• Border measures could lead to the detention of imports or exports of generic medicines suspected of infringing intellectual property rights, disrupting supply chains.

Key Concepts Involved:

• Data Exclusivity: Prevents generic drug manufacturers from relying on the originator's clinical trial data for a set period, delaying generic entry.
• Patent Term Extension: Extends the duration of a patent beyond its original term, usually to compensate for regulatory delays in drug approval.
• Compulsory License: Authorizes a party to produce a patented product without the patent holder's consent, typically for public health reasons.